Trial of IGF-1R Inhibitor Figitumumab Combined with Carbo/Taxol Officially Closed
The trial of the insulin-like growth factor-1 receptor (IGF-1R) inhibitor figitumumab in combination with carbo/taxol as first line therapy for advanced NSCLC was officially closed after it was determined that the experimental arm would not have a meaningful chance of appearing su